The FDA has started a review of Bristol-Myers Squibb's immunotherapy duo Opdivo and Yervoy as a therapy for newly diagnosed unresectable liver cancer that could see a return to the category for the ...
Bristol-Myers Squibb has acquired rights to an “armed virus” targeting cancer from UK biotech, PsiOxus Therapeutics, worth more than $900 million if the project is successful. BMS will pay PsiOxus $50 ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Storm Center 7’s Live Doppler 7 Radar has the latest conditions in your neighborhood to help you plan, prepare, and act when severe weather arrives. News Center 7 will continue coverage of all the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results